CClinicalTrials.gg
RecruitingNCT06828276i-CBTUpdated Dec 12, 2025

Culturally Adapted i-CBT for Farsi/Dari Speaking Migrants

An interventional study of Culturally adapted i-CBT in Depressive Symptoms, Anxiety Symptoms and Grief, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 15 Years to 29 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
15 Years to 29 Years
Sex
All
01

Study summary

The aim of this randomized controlled trial (RCT) is to investigate the effectiveness of a culturally adapted internet-based cognitive behavioral therapy (i-CBT) intervention in reducing symptoms of common mental health issues among Farsi/Dari-speaking youth migrants and refugees. Investigator hypothesizes that there will be a significant decrease in psychological symptoms after participants receive the intervention compared to a control group.

Read the detailed description

Participants who are included in the study will be allocated to the experimental group and the control group (waiting list). Participants will be invited to participate tailored i-CBT intervention over 10-weeks. Intervention covers common psychological issues. Participants will have access to support through a chatting function, during the interventional period. Intervention effects will be measured prior-treatment, post-treatment, and 6 months post-treatment.

02

Conditions studied

  • Depressive Symptoms
  • Anxiety Symptoms
  • Grief
  • Psychological Trauma
  • Insomnia
  • Resilience
  • Stress
  • Psychological Well Being
  • Marital Relationship
  • Wellbeing
  • Common Mental Health Problems
  • Rumination

Keywords

  • Refugee
  • Cognitive behavioral therapy
  • Psychological problems
  • Persian speaking
  • Psychological well-being
  • Youth
  • Mental problems
  • Resilience
  • Asylum seeker
03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's planned enrollment of 128 is above the median of 84 across 6,720 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,113 studies on the registry; 267 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Between the ages of 15 and 29.
  • A score above the cut-off 1.75 on HSCL-25
  • Has a refugee or migrant background
  • Has a good and stable internet connection
  • Has access to a computer, tablet or smartphone
  • Is fluent in reading and writing Arabic
  • Has the ability to dedicate time to take part in the intervention for 6-10 weeks.

Exclusion criteria

Exclusion Criteria:

  • Is suffering from a severe mental illness, such as psychosis or severe depression.
  • Is suffering from substance abuse
  • Is undergoing a psychological treatment
  • Has a high risk of suicide
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Active group

    Tailored I-CBT for mild to moderate common mental health problems over a 10-weeks-period.

    Behavioral: Culturally adapted i-CBT

  • No intervention
    Waiting-list

    Control group

Interventions

  • BehavioralCulturally adapted i-CBT

    A culturally and language adapted i-CBT intervention for Farsi/Dari speaking youth migrants and refugees. The intervention targets mild to moderate common mental health problems.

06

What researchers measure

Primary outcomes

  1. Hopkins Symptom Checklist-25 (HSCL-25)

    Assessment of anxiety and depressive symptoms. HSCL-25 consists of 25 items.Each item is rated on a scale from 1 to 4, where 1 means "Not at all" and 4 means "Extremely".Higher scores indicate a worse outcome, as they reflect greater severity of symptoms.

    Time frame: Pre-intervention, up to 5 weeks, immediately after the intervention, 6 months after completion of the intervention

Secondary outcomes

  1. Psychological Outcome Profiles (PSYCHLOPS)

    Impact of problematic area on function. PSYCHLOPS questionnaire consists of 4 items. These items are designed to capture the patient's main problem, the impact of this problem on their daily life, and their overall well-being. Each question in PSYCHLOPS is scored on a scale from 0 to 5, where 0 indicates no problem and 5 indicates the most severe problem. Higher scores indicate a worse outcome, as they reflect greater severity of problems or distress.

    Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention

  2. Insomnia Severity Index (ISI)

    Assessment of severity of insomnia symptoms. ISI consists of 7 items, each rated on a scale from 0 to 4.Higher scores indicate a worse outcome, as they reflect more severe insomnia symptoms.

    Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention

  3. Prolonged Grief Disorder (PG-13)

    Assessment of prolonged grief disorder. The PG-13 consists of 13 items, each rated on a scale from 1 to 5, where 1 means "Not at all" and 5 means "Several times a day". Higher scores indicate a worse outcome, as they reflect more severe symptoms of prolonged grief.

    Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention

  4. Posttraumatic Stress Disorder Checklist (PCL-5)

    Assessment of symptoms of post-traumatic stress disorder. The PCL-5 consists of 20 items, each rated on a scale from 0 to 4. The total score ranges from 0 to 80. Higher scores indicate a worse outcome, as they reflect greater severity of PTSD symptoms.

    Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention

  5. The World Health Organization-Five Well-Being Index (WHO-5)

    Assessment of subjective psychological well-being.The WHO-5 consists of 5 items, each rated on a scale from 0 to 5. Higher scores indicate a better outcome, as they reflect higher levels of well-being.

    Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention

  6. Brief Resilience Scale (BRS)

    Assessment of resilience.The BRS consists of 6 items, each rated on a scale from 1 to 5. Higher scores indicate a better outcome, as they reflect greater resilience.

    Time frame: Pre-intervention, immediately after the intervention, 6 months after completion of the intervention

  7. Client Satisfaction Questionnaire (CSQ-3)

    Assessment of the levels of satisfaction of the participant with the intervention.CSQ-3 consists of 3 items. Each item is rated on a scale from 1 to 4. Higher scores indicate a better outcome, as they reflect greater satisfaction with the services received.

    Time frame: Immediately after the intervention, 6 months after completion of the intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Demetry Y, Wasteson E, Lindegaard T, Abuleil A, Geranmayeh A, Andersson G, Shahnavaz S. Individually Tailored and Culturally Adapted Internet-Based Cognitive Behavioral Therapy for Arabic-Speaking Youths With Mental Health Problems in Sweden: Qualitative Feasibility Study. JMIR Form Res. 2023 Nov 24;7:e46253. doi: 10.2196/46253. PubMed 37999955 ↗
  • Lindegaard T, Wasteson E, Demetry Y, Andersson G, Richards D, Shahnavaz S. Investigating the potential of a novel internet-based cognitive behavioural intervention for Dari and Farsi speaking refugee youth: A feasibility study. Internet Interv. 2022 Apr 1;28:100533. doi: 10.1016/j.invent.2022.100533. eCollection 2022 Apr. PubMed 35433279 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06828276
Lead sponsor
Karolinska Institutet
Collaborators
Linkoeping University
Responsible party
Shervin Shahnavaz (PhD, Lecturer, Karolinska Institutet) — Principal investigator
First posted
Feb 14, 2025
Start date
Mar 25, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 12, 2025

Study contacts

Shervin Shahnavaz, PhD
Contact
shervin.shahnavaz@ki.se
0046722154769
Anahita Geranmayeh, MSc
Contact
Anahita.geranmayeh@ki.se
0046737121661
Gerhard Andersson, PhD
principal investigator · Linkoeping University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion